Cholangiocarcinoma Market Players:
- Verismo Therapeutics, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- AstraZeneca plc
- Merck Sharp & Dohme LLC.
- Basilea Pharmaceutica Ltd.
- Incyte Corporation
- Agios Pharmaceuticals Inc.
- Specialised Therapeutics Asia Pte Ltd (ST)
- PlantPraxis Biotecnologia
- Dr. Reddy’s Laboratories Ltd.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of cholangiocarcinoma is evaluated at USD 664.02 million.
The global cholangiocarcinoma market size exceeded USD 583.65 million in 2025 and is set to expand at a CAGR of over 15.3%, surpassing USD 2.42 billion revenue by 2035.
North America’s cholangiocarcinoma market will secure around 35% share by 2035, driven by approval of new drugs and increased R&D activity in healthcare.
Key players in the market include Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme Corp, Basilea Pharmaceutica, Incyte Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, Dr. Reddy’s Laboratories Ltd..
